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Vaccination  is  being  considered  as part  of a sustainable  strategy  for the  control  of  bovine  tuberculosis
(BTB)  in the  UK. The  live  attenuated  Mycobacterium  bovis  bacillus  Calmette-Guerin  (BCG)  has  been  used
experimentally  to vaccinate  cattle  against  BTB.  However,  BCG  confers  partial  protection  against  BTB
and  therefore,  there  is a need  to develop  improved  vaccines.  BTB  vaccine  efﬁcacy  experiments  require
the  use  of  biosafety  level  3  facilities  which  are  expensive  to  maintain,  generally  oversubscribed  and
represent  a  bottle  neck  for the testing  of  vaccine  candidates.  One  indicator  of  the  induction  of  protective
responses  would  be  the ability  of the host’s  immune  response  to control/kill  mycobacteria.  In  this  work
we  have  evaluated  an  intranodal  BCG  challenge  for the  selection  of  vaccine  candidates  at  biosafety  level
2  which  are  capable  of  inducing  mycobactericidal  responses.  To  our  knowledge,  this  is the  ﬁrst  such
report.  Whilst  BCG  only  confers  partial  protection,  it is  still  the  standard  against  which  other  vaccines
are  judged.  Therefore  we tested  the  BCG  intranodal  challenge  in  BCG  (Danish  strain)  vaccinated  cattle
and  showed  that vaccinated  cattle  had  lower  BCG  cfu  counts  than  naïve  cattle  at  14  and 21 days  after
intranodal  challenge  with  BCG (Tokyo  strain).  This  model  could  help  prioritize  competing  TB vaccine
candidates  and  exploration  of primary  and  secondary  immune  responses  to  mycobacteria.
Crown  Copyright  © 2014  Published  by  Elsevier  Ltd.  This  is  an open  access  article  under  the  CC  BY
license  (http://creativecommons.org/licenses/by/3.0/).. Introduction
Mycobacterium bovis belongs to the Mycobacterium tuberculo-
is complex of bacteria and is the main aetiologic agent of bovine
uberculosis (BTB) as well as being responsible for a proportion of
ases of human tuberculosis (TB). Despite the application of the
est and slaughter policy, the incidence of BTB in GB has increased
teadily since the 1980s and this is thought to be due to the
xistence of a wildlife reservoir [1]. Hence, vaccination is being
onsidered as an additional tool to contribute to the control of BTB
2]. The live attenuated strain M.  bovis bacillus Calmette-Guerin
BCG) was derived from a case of bovine tuberculoid mastitis in the
arly 1900s and has been used as a vaccine against TB in humans
ince 1921 [3]. BCG has been used experimentally for vaccination
f cattle against BTB since 1912, including in the UK in the ﬁrst
alf of the 20th century [4,5]. As in humans, BCG confers partial
rotection against BTB in cattle [6] and therefore, there is a need
∗ Corresponding author. Tel.: +44 0 1932 359 529; fax: +44 0 1932 357 260.
E-mail address: Bernardo.Villarreal@ahvla.gsi.gov.uk (B. Villarreal-Ramos).
ttp://dx.doi.org/10.1016/j.vaccine.2014.08.009
264-410X/Crown Copyright © 2014 Published by Elsevier Ltd. This is an open access artfor better vaccines. It is possible to carry out vaccination and chal-
lenge experiments in cattle to determine whether a given vaccine
or vaccination regimen confers protection against BTB. However,
these experiments require the use of large animal biosafety level
3 (BSL3) facilities which are expensive to maintain and are often
oversubscribed. Ideally, cheaper and faster gating criteria should
be available to support the decision making process of whether a
vaccine should be tested in cattle for protective efﬁcacy in such
vaccination and challenge experiments. This would considerably
accelerate vaccine development.
Although BCG is attenuated, it is a live bacterium which repli-
cates and survives in the host [3] and is normally handled in BSL2
facilities. If a vaccine is to be successful in conferring protection
against challenge with virulent M. bovis, it should induce immune
responses capable of controlling/killing mycobacteria and it is rea-
sonable to propose that this could initially be demonstrated by an
ability to induce a reduction in the number of BCG cfu. Recently,
a human BCG challenge model for the testing of TB vaccine can-
didates has been described [7,8]. We  proposed that such a BCG
challenge model in cattle, once developed, could serve as a gat-
ing criterion for this target species to screen vaccines before they
icle under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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re tested in expensive and facility-intense M. bovis challenge
xperiments. This paper describes the development of a cattle BCG
hallenge model.
. Materials and methods
.1. Cattle
Experimentation was carried out according to the UK Animal
Scientiﬁc Procedures) Act 1986. The study protocol was approved
y the AHVLA Animal Use Ethics Committee (UK Home Ofﬁce PCD
umber 70/6905).
Holstein-Friesian cattle of 4–6 months of age were sourced from
arms known to be free of BTB.
.2. Mycobacteria
The vaccine strain M.  bovis BCG Danish 1331 was prepared as
er manufacturer’s instructions (SSI, Denmark). BCG Danish 1331
s currently the only BCG strain commercially available for vacci-
ation.
The BCG challenge strain was BCG Tokyo (a kind gift from Dr. M
ehr, McGill University, Canada), which was grown to mid  log phase
n 7H9 medium containing 0.05% Tween 80 (Sigma-Aldrich, Poole,
nited Kingdom) and ADC and stored frozen at −70 ◦C until further
se. BCG Tokyo differs from BCG Danish 1331 at the RD2 and this
ifference would permit the distinction between the two  strains in
accination and challenge experiments. An aliquot was thawed and
erial dilutions plated on 7H11 agar medium to determine bacterial
iter. Frozen BCG Tokyo titer was determined to be at 1 × 107 cfu/ml.
noculum of BCG Tokyo used for challenge as well as selected
olonies recovered from harvested lymph nodes were typed to
onﬁrm strain genotype. Samples were heat-inactivated at 80 ◦C
nd used as template in a PCR reaction using HotStarTaq Master
ix  (Qiagen, United Kingdom) and three oligonucleotide primers
RD2 FW FlankFW, 5′-att gcg aac acg gga cgt cg-3′; RD2 FlankRev,
′-gtt cgc cac aac ccg gaa cg-3′; RD2 InternalFW, 5′-gct cgt gtt tga
at cgg cg-3′) for large sequence polymorphism typing of the RD2
egion [9]. PCR products of 196 bp and 319 bp deﬁned the tested
CG isolates as RD2 intact (e.g. BCG Tokyo) and deleted (e.g. BCG
SI), respectively.
.3. Vaccination and challenge experiments
Challenge experiment 1: For evaluation of optimal inoculation
osage, 16 animals were inoculated into the prescapular lymph
ode, which can be easily felt by palpation of the animal around
he prescapular area; the lymph node was located and raised and
he skin above the node was clipped and the node injected through
he skin (please see Supplemental video). Animals were inoculated
t day 0 with 107 and 108 cfu BCG Tokyo in 1 ml  of 7H9 medium in
he left and right prescapular nodes, respectively.
Challenge experiment 2: For vaccination and challenge, 48 ani-
als were divided into four groups of 12 animals each; two of
hese groups were inoculated subcutaneously (s.c.) with 1-2 × 106
CG SSI in 0.5 ml  Sauton’s diluent in the left prescapular area. The
ther two groups were used as naïve controls; after eight weeks all
8 animals were inoculated in the right prescapular lymph node
ith between 1.8 × 108 and 2.2 × 108 cfu BCG Tokyo as indicated
bove.
.4. Evaluation of immune responsesImmune responses were evaluated as production of interferon
amma  (IFN) and IL-17 in whole blood as described elsewhere
10]. Brieﬂy, peripheral blood was withdrawn from the jugular veinne 32 (2014) 5645–5649
and placed in a tube containing sodium heparin (Leo laboratories)
to a ﬁnal concentration of 10,000 U/ml. Two hundred and twenty
microliter of blood was  incubated with 25 l RPMI1640 medium
alone (negative control [NC]) or with 25 l M.  bovis puriﬁed protein
derivative (PPD-B) (10 g/ml) (Prionics, Schlieren, Switzerland)
and incubated at 37 ◦C in a 5% CO2 and 95% humidity atmosphere.
After overnight incubation, blood was  centrifuged at 300 × g for
10 min  and plasma harvested and stored at −20 ◦C until use. Secre-
tion of IFN was  determined using the BovigamTM assay (Prionics).
Secretion of IL-17 was determined following the manufacturer’s
instructions (Kingﬁsher Biotec, MN,  USA). Results are expressed as
mean O.D. values ± standard error of the mean.
2.5. Determination of bacterial load in lymph nodes
After trimming, lymph nodes were submerged brieﬂy in 70%
ethanol prior to weighing and slicing for processing in a stom-
acher (Seward) for 2 min  with 7 ml  of PBS. Macerate was used to
prepare serial dilutions for plating on modiﬁed 7H11 agar plates
[11]. Results are presented as counts per ml.
2.6. Statistical analysis
Graph drawing and statistical analysis were carried out using
GraphPad Prism v 5.02 (GraphPad Software, San Diego, CA) and
GraphPad Instat v 3.06; for IFN secretion a Mann–Whitney ANOVA
was carried out; for bacterial counts an unpaired T-test with Welch
correction (signiﬁcance indicated by * p < 0.05, ** p < 0.01 or ***
p < 0.001 on the graphs). Statistical analysis for the spread of BCG
to other lymph nodes was  carried out with two  sided contingency
tables using Fischer exact test.
3. Results
3.1. Intranodal inoculation allows recovery of BCG
To deﬁne the optimal dose and harvest time of the challenge
organism, BCG Tokyo, 16 non-vaccinated cattle were inoculated
intranodally with 107 and 108 cfu BCG Tokyo directly in the left and
right prescapular lymph nodes, respectively. Lymph nodes, from
four animals at each time point, were harvested at post-mortem
1, 7, 14 and 21 at days after inoculation. Fig. 1 shows the recov-
ery of BCG from the prescapular lymph nodes at the different time
points of harvest. Fig. 1A shows data following inoculation with
108 cfu BCG Tokyo and Fig. 1B shows data following inoculation
with 107 cfu BCG Tokyo. Based on the observed data, we  decided
to undertake a proof of concept experiment in which cattle would
be vaccinated with BCG Danish and challenged intanodally after
8 weeks with 108 cfu BCG Tokyo and lymph nodes would be har-
vested at 2 and 3 weeks post-challenge (see below).
3.2. Immune responses to PPD-B induced by vaccination with
BCG SSI and challenge with BCG Tokyo
Based on the data from the experiment above, 48 cattle were
divided into four groups of 12 animals each. Two  groups were used
as naïve controls and two  groups were vaccinated subcutaneously
(s.c.) in the left ﬂank as described in materials and methods. To
demonstrate vaccine take, the production of IFN and IL-17 after
in vitro stimulation of whole blood with PPD-B was evaluated. Both,
IFN (Fig. 2A) and Il-17 (Fig. 2B) were induced by vaccination with
BCG. Responses to PPD-B were detectable in all vaccinated animals
at week 4 and increased at week 8. No responses were detectable
in naïve animals during this time period. IFN and IL-17 responses
in naïve animals were induced by intranodal injection with BCG
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Fig. 1. Recovery of BCG from prescapular lymph nodes. Cattle, four per time point, were inoculated with 108 or 107 BCG Tokyo cfu in the right (A) or left (B) prescapular
lymph  nodes. Lymph nodes were harvested at the time points indicated in the x axis and macerated as indicated in material and methods. Dilutions of lymph node macerates
were  plated in 7H11 agar plates for determining recovery of BCG. Bars represent the means and SEM.
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counts ranged from 2.041 log10 cfu to 5.38 log10 cfu with a median
of 4.688 log10 cfu. At three weeks, the bacterial load in the right
prescapular lymph node of naïve cattle ranged from 3.587 log10
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Fig. 3. Inﬂammation, measured as increased weight of BCG-challenged lymphig. 2. IFN secretion responses in whole blood following vaccination of cattle 
ubcutaneously and peripheral blood not stimulated (closed symbols) (US) or stim
sed  in a BovigamTM assay as indicated in materials and methods. Symbols represe
okyo, whilst previous BCG responses induced by BCG SSI in vacci-
ated animals were boosted at week 9.
.3. Detection of BCG Tokyo in lymph nodes
Eight weeks after vaccination, naïve and vaccinated animals
ere inoculated into the right prescapular lymph node with c
 × 108 cfu BCG Tokyo. To harvest lymph nodes, one group of BCG-
accinates and one group of naïve control animals were killed at
 weeks post-challenge and one group of BCG-vaccinates and one
roup of naïve control animals were killed at week 3 post-challenge.
rescapular, submandibular and popliteal lymph nodes were har-
ested at post-mortem. Fig. 3 shows the weights, as a measure
f inﬂammation and cellular congestion, of the right prescapular
ymph nodes; the nodes in which BCG Tokyo was injected. Whilst
o signiﬁcant difference in weight was detected in the lymph nodes
rom naïve and BCG-vaccinated cattle at week 2, corresponding
omparison for week 3 showed that there was a statistically sig-
iﬁcant difference. At week 3 the lymph nodes from naïve animals
ere heavier ( = 0.0008); ranging from 12.51 g to 29.3 g with a
edian of 22.18 g while lymph nodes obtained from vaccinated
nimals ranged from 2.9 g to 19.89 g with a median of 15.52 g.
Fig. 4 shows the bacterial counts from the right prescapularymph nodes from naïve and BCG-vaccinated cattle at 2 and 3
eeks after inoculation. Lymph nodes from vaccinated animals
howed statistically signiﬁcantly lower bacterial counts at weeks
 ( = 0.0107) and 3 ( = 0.0439) compared to lymph nodes fromCG SSI. Cattle were vaccinated (triangles) or not (circles) with 106 cfu BCG SSI
 (open symbols) with PPD-B (PPD). Supernatants from blood were harvested and
 mean for each group and bars the SEM.
control animals after challenge. At week 2, the bacterial load in
the right prescapular lymph nodes of naïve cattle ranged from
3.954 log10 cfu to 5.838 log10 cfu with a median of 5.431 log10 cfu;
in the right prescapular lymph nodes from BCG-vaccinated cattlenodes, is greater in lymph nodes from naïve than from vaccinated animals. After
challenge of naïve (circles) and BCG-vaccinated (triangles) cattle, prescapular lymph
nodes were harvested at weeks 2 (closed symbols) and 3 (open symbols) and
weighed. Results are presented for each individual animal and thick bars represent
the  mean for each group. *** p—0.0008 (unpaired T-test with Welch correction).
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Fig. 4. Bacterial counts, following BCG Tokyo challenge, are lower in vaccinated than
in  naïve animals. Eight weeks after BCG vaccination naïve (circles) and vaccinated
animals (triangles) were injected intranodally with c 1 × 108 cfu BCG Tokyo and
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esults are presented for each individual animal and thick bars represent the mean
or  each group. * p = 0.0107; * p = 0.0439 (unpaired T-test with Welch correction).
fu to 5.068 log10 cfu with a median of 4.648 log10 cfu; in the
ight prescapular lymph nodes from BCG-vaccinated cattle counts
anged from 2.591 log10 cfu to 4.944 log10 cfu with a median of
.8 log10 cfu. The number of BCG cfu recovered from naïve animals
t week 2 was higher than the cfu recovered at week 3; this differ-
nce was statistically signiﬁcant ( = 0.0109). On the other hand, no
ifference was found in BCG cfu recovered at week 2 compared to
eek 3 in BCG vaccinated animals.
It was of interest to determine the distribution of the bacteria
ollowing challenge with BCG-Tokyo. To that effect, as well as evalu-
ting bacterial counts in the right prescapular lymph nodes, counts
ere also evaluated in left prescapular lymph nodes and in left and
ight submandibular and popliteal lymph nodes. Table 1 shows the
roportion of animals presenting bacterial counts in the different
ymph nodes according to time and treatment. The data indicate
hat the dissemination of BCG Tokyo was greater in naïve control
nimals compared to animals that had been vaccinated with BCG
t week 0. The differences at both 2 and 3 weeks were statistically
igniﬁcant ( = 0.0017 and  = 0.0005, respectively).
. Discussion
Vaccination and challenge experiments are a necessity for the
evelopment of vaccines against bovine TB. However, these exper-
ments involve the use of large animal BSL3 facilities. Whilst
ecessary, due to their nature, these facilities are expensive to run
nd limited in number and therefore represent a bottle neck for the
esting of vaccine candidates. Development of a model in the target
pecies, cattle, for prioritizing vaccines under lower containment
onditions would save money as BSL2 facilities are cheaper to run
han BSL3 facilities. Being an attenuated strain of M.  bovis it would
e expected that cattle would at some stage control BCG and there-
ore the BCG challenge experiments would be shorter than standard
irulent M.  bovis challenge experiments. Further, by reducing the
able 1
acterial counts in lymph nodes to which mycobacteria could have spread. Data
hown are number of animals in which at least one cfu was counted over the total
umber of animals inoculated with BCG Tokyo. Notice that the number of animals
ith bacterial counts is greater in the non-vaccinated than in the BCG vaccinates.
Lymph
node
Week 2 Week 3
Non-vaccinated BCG Non-vaccinated BCG
Left prescapular 8/12 3/12 6/12 1/12
Left  submandibular 1/12 0/12 1/12 0/12
Right submandibular 2/12 0/12 2/12 0/12
Left  popliteal 4/12 1/12 4/12 1/12
Right popliteal 3/12 0/12 3/12 0/12ne 32 (2014) 5645–5649
need for BSL3 experimentation, vaccine development programmes
could be signiﬁcantly accelerated.
An initial step for the development of such a model requires
the establishment of a baseline for the consistent and reliable
recovery of mycobacteria from bovine tissues. Previous attempts in
this laboratory to recover BCG from cattle following s.c. challenge
proved inconsistent. It is thought that following s.c. inocula-
tion mycobacteria would migrate to the lymph node draining
the site of inoculation; however, after inoculation, mycobacteria
could disperse within the subcutaneous area and it is possi-
ble that mycobacteria could migrate to more than one node. By
using intranodal inoculation, we have reduced the possibilities
of mycobacteria dispersing within the subcutaneous areas and
migrating to nodes other than the lymph node injected. To our
knowledge, the experiment described in Fig. 1 is the ﬁrst time in
which a time curve, albeit partial to day 21, on the recovery of BCG
from cattle has been reported. Thus, this is the ﬁrst report for the
relatively consistent recovery of BCG from cattle in quantiﬁable
numbers.
This protocol was  then used to determine whether prior vac-
cination using BCG SSI would affect the recovery of BCG after
challenge compared to naïve animals in a manner similar to a
standard efﬁcacy vaccine test where virulent M. bovis is used for the
challenge phase. Given the volume of literature and our previous
experience, we decided to use BCG SSI as the test vaccine in these
proof-of-principle experiments. We  also decided to harvest lymph
nodes after 2 and 3 weeks as we reasoned that this would be sufﬁ-
cient time for immune responses induced by previous vaccination
to have an impact on the control of the BCG challenge and would
maximise our ability to detect differences between vaccinated and
non-vaccinated animals. On a group basis, prior BCG vaccination
did reduce the number of mycobacteria recovered from vaccinated
animals compared to non-vaccinated animals. However, from Fig. 4,
it is clear that there was  animal to animal variation in both vacci-
nated and naïve animals following inoculation with BCG Tokyo. It
is also clear that not all BCG-vaccinated animals were protected
to the same extent. It is possible to divide the animals into pro-
tected and not-protected by considering all BCG vaccinates with
cfu counts lower than the animal presenting the lowest cfu counts
in the non-vaccinated group as protected; all other BCG vacci-
nates could be considered as not protected. Using this criterion,
4/12 animals would have been protected by BCG vaccination after
2 weeks; at 3 weeks, 6/12 animals would have been protected.
This outcome therefore parallels the outcome of vaccinated ani-
mals after challenge with M. bovis, with a proportion of animals
presenting with pathology not indistinct from naïve control ani-
mals, and another proportion of animals presenting without or with
signiﬁcantly reduced pathology compared to naïve cattle [12,13].
It is of interest that intranodal inoculation of naive cattle with
BCG induced immune responses to PPD-B as early as one week
after injection (week 9 for previously non-vaccinated animals). As
observed in the BCG vaccinated group, IFN and IL-17 responses can
be detected at between 2 and 4 weeks after vaccination [10,14,15].
It is not clear whether this phenomenon was  due to the higher dose
used during challenge or to the intranodal route of inoculation or
that BCG Tokyo for challenge was derived from frozen logarithmic
growth phase liquid stocks, whilst for vaccination lyophilised BCG
SSI was resuspended in Sauton’s medium. Intranodal inoculation
has been reported to be more immunogenic than the intradermal
or intravenous routes of immunisation [16,17] and it is possible that
this route of inoculation may  induce stronger immune responses
than those normally induced by BCG which may  translate into
greater protection against M. bovis. Future experiments will be nec-
essary to test this hypothesis.
Whilst it was not the purpose of this study to establish the
extent of dissemination of BCG in cattle, these experiments provide
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vidence that BCG spreads to organs other than those directly inoc-
lated. However, it is important to state that these results cannot
e correlated to what would happen following subcutaneous vac-
ination due to the following reasons: the strain used for challenge
as BCG Tokyo from frozen mid-log liquid cultures whilst BCG SSI,
he strain used for vaccination, is genetically different and was used
s a lyophilised suspension. The dose used for vaccination was  100
old lower than the dose used for challenge and the vaccine was
dministered s.c. whilst the challenge was given intranodally. It is
lso worth pointing out that, after challenge, BCG Tokyo was  more
idely distributed in non-vaccinated cattle than in vaccinated cat-
le. The bacteria obtained from lymph nodes other than the right
rescapular lymph node, the site of injection, were conﬁrmed by
enetic typing to be BCG Tokyo and not BCG SSI (results not shown).
hus, we did not detect BCG SSI in the lymph nodes examined in
hese experiments at 10 (week 2 after challenge) and 11 (week 3
fter challenge) weeks after s.c. inoculation.
In conclusion, this target species model can be used as a gat-
ng system for vaccine candidates prior to further testing in BSL 3
acilities using virulent M.  bovis challenge. This model could also
e used to further explore the bovine primary and secondary ele-
ents of an immune response against mycobacteria in order to
etermine which factors are important in the control and/or killing
f mycobacteria.
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